Boston Scientific Corp. (NYSE:BSX) was granted U.S. Food & Drug Administration approval for leads designed for use in its Precision Plus spinal cord stimulator system.
The Linear 3-4 and Linear 3-6 leads, when combined with the recently approved W4 and D4 lead splitters, provide physicians with the broadest range of percutaneous lead configurations in the industry, according to the company.